US20040142873A1 - Cosmetic or dermatological use of peptides for promoting adhesion between skin cells - Google Patents
Cosmetic or dermatological use of peptides for promoting adhesion between skin cells Download PDFInfo
- Publication number
- US20040142873A1 US20040142873A1 US10/755,277 US75527704A US2004142873A1 US 20040142873 A1 US20040142873 A1 US 20040142873A1 US 75527704 A US75527704 A US 75527704A US 2004142873 A1 US2004142873 A1 US 2004142873A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- composition
- cosmetic
- gln
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- 210000004927 skin cell Anatomy 0.000 title claims abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 16
- 230000001737 promoting effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 44
- HJARVELKOSZUEW-YUMQZZPRSA-N Gly-Pro-Gln Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJARVELKOSZUEW-YUMQZZPRSA-N 0.000 claims abstract description 23
- 210000003491 skin Anatomy 0.000 claims abstract description 23
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000032683 aging Effects 0.000 claims abstract description 10
- 230000021164 cell adhesion Effects 0.000 claims abstract description 10
- 230000037075 skin appearance Effects 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 235000012216 bentonite Nutrition 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 235000012222 talc Nutrition 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 17
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 10
- 210000002744 extracellular matrix Anatomy 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002431 foraging effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003280 chronobiological effect Effects 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- -1 thinners Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the invention concerns the uses for the preparation of a cosmetic or dermatological composition, of a sufficient amount of peptide of sequence (Gly-Pro-Gln) n -NH 2 , wherein n ranges between 1 and 3, and where the amino acids can be in the L, D, or DL configuration; the peptides or the composition being designed to:
- [0004] provide curative and/or preventive treatment for aging skin symptoms (of physiological or solar origin) and to enhance skin appearance.
- said peptide is of the sequence (Gly-Pro-Gln) 2 -NH2.
- Cutaneous aging is a complex phenomenon due to many intrinsic and extrinsic factors. Clinically, wrinkles and fine lines appear, as well as a loss of cutaneous elasticity, a slackening of cutaneous and subcutaneous tissues . . .
- the collagen is a principal element of the extracellular matrix and takes part in skin structure and consistency. Collagen is studies a lot for its many functions and is also abundantly used in cosmetics.
- the main subject of the invention is the use for preparing a cosmetic or dermatological composition, of a sufficient amount of peptide of sequence (Gly-Pro-Gln) n -NH 2 , wherein n ranges between 1 an 3, and where the amino acids can be in the L, D, or DL configuration ; the peptides or the composition being designed to increase cell adhesion.
- the peptides or the composition are designed to promote adhesion between cutaneous cells.
- the term “cellular adhesion” intends, on the one hand, the adhesion between cells and the extracellular matrix, and, on the other hand, the adhesion of cells between them.
- the term “adhesion between the cutaneous cells”, intends, on the one hand, the adhesion between cutaneous cells and the extracellular matrix, and on the other hand, the adhesion of cutaneous cells between them.
- the expression “to increase cell adhesion”, intends the stimulation of the protein expression aiming at reinforcing cell adhesion and enriching the extracellular matrix with proteins which compose it.
- the peptide or the composition according to the invention increases the protein expression of the extracellular matrix.
- proteins of the extracellular matrix proteins such as collagen, fibronectin, laminin or elastin. All these proteins are constitutive of the matrix and play a fundamental role.
- the laminin-5 interacts with the integrins of basal keratinocytes, which permit thus to anchor the cells on the two-dimensional network of the dermo-epidermal junction.
- Cell adhesion is carried out, in particular, thanks to membrane glycoproteines, the integrins. These proteins interact with various molecules of the extracellular matrix, like fibronectin or laminin. They are involved in the keratinocyte adhesion to the extracellular matrix, in the connections between cells and in the basement membrane cohesion of the skin. Thus, an increase in the adherent capacity of the cutaneous cells can indicate an increase of the integrin expression.
- the reinforcement of the cell adhesion makes it possible to preserve the structure of collagen fibers and to fight cutaneous atrophy due to aging, in particular with photoinduced aging.
- the peptide acts on cohesion, communication and on the three-dimensional organization of the cutaneous tissues, thus supporting the fight against the structural disorganization due to cutaneous aging.
- the invention also concerns the uses for preparing a cosmetic or dermatological composition, of an effective amount of peptide of sequence (Gly-Pro-Gln) n -NH 2 , wherein n ranges between 1 an 3, and where the amino acids can be in the L, D, or DL configuration; the peptides or the composition being designed to provide curative and/or preventive treatment for aging skin symptoms and to enhance skin appearance.
- the expression “to enhance skin appearance” intends all the phenomena which are likely to have for consequences a visual improvement of the skin's aspect.
- the skin will have a nicer appearance; it will be, for example, much more beautiful, firm and/or smooth. All the small imperfections will be decreased or removed.
- the papyraceous aspect of the skin for example, will be attenuated.
- the term “cutaneous signs of aging” intends any modification in the external appearance of the skin due to aging, whether chronobiological and/or photoinduced, such as, for example wrinkles and fines lines, withered skin, flabby skin, thinned skin, or lack of elasticity and/or tonicity of the skin, but also all internal modifications of the skin which do not result systematically in a modified external appearance, such as, for example, all internal damages of the skin, particularly to collagen, resulting from ultraviolet radiations exposure.
- Skin aging can be, for example, a quantitative and a qualitative deterioration of interactions between the various components of the extracellular matrix, and can result in the appearance of wrinkles and fine lines. These deteriorations are particularly severe in areas exposed to UV. Indeed, fibroblasts exposed to UV adhere slightly more to fibronectin, and has as a consequence a degradation of collagen fibers.
- said peptide is of the sequence (Gly-Pro-Gln) 2 -NH 2 .
- the invention relates to the use such as previously defined characterized by the fact that the peptide is in a protected form or not.
- the protection used is either the acylation of the N-terminal amine group, or the esterification of the terminal carboxyl group, or both of them.
- amino acids constituting the peptide according to the invention, can be under configuration L and D; in a preferential way, amino acids have L configuration.
- the peptide according to the invention can be in L, D, or DL configuration.
- Peptides the objects of this patent, can be obtained either by traditional chemical synthesis (in solid phase or in homogeneous liquid phase), or by enzymatic synthesis (Kullman and Al, J Biol. Chem. 1980, 225, 8234) from constitutive amino acids or their derivatives.
- Peptides of this invention can still be obtained by biotechnology (use of a micro-organism, modified or not by genetic engineering); i.e., peptides according to this invention can also be obtained by fermentation of a strain of bacteria, modified or not, by genetic engineering to produce peptides of sequence previously mentioned and their fragments.
- Peptides of this invention can also be obtained from natural proteins; i.e. by protein extraction of animal or vegetable origin, followed by controlled hydrolysis which releases the peptide fragments of average size and of small size, with the condition that the released elements must contain at least the sequence (Gly-Pro-Gln)-NH 2 .
- the peptide of the invention may be of natural or synthetic origin.
- the peptide of the invention is obtained by chemical synthesis.
- the peptide is solubilized beforehand in one or more solvents compatible with use in the cosmetic or the pharmaceutical field, such as water, glycol propylene, glycol butylene, diglycols ethoxylated or propoxylated , ethanol, propanol or isopropanol.
- solvents compatible with use in the cosmetic or the pharmaceutical field such as water, glycol propylene, glycol butylene, diglycols ethoxylated or propoxylated , ethanol, propanol or isopropanol.
- the peptide is solubilized beforehand in one or more vectors such as liposomes or adsorbed on powdery organic polymers, mineral supports like talcs and bentonites, and more generally solubilized in, or fixed on, any vector compatible with use in the cosmetic or the pharmaceutical field.
- vectors such as liposomes or adsorbed on powdery organic polymers, mineral supports like talcs and bentonites, and more generally solubilized in, or fixed on, any vector compatible with use in the cosmetic or the pharmaceutical field.
- the composition can be a cosmetic or a dermatological or a pharmaceutical composition.
- the composition is a cosmetic composition, because it is intended to improve the aspect and the general cutaneous performances of the skin.
- composition is preferentially a cosmetic and/or a dermatological composition, adapted to a cutaneous administration, including a medium compatible with a use in the cosmetics or the pharmaceutical field.
- the invention concerns the mammals in general and, more particularly, human beings.
- the effective amount of the active ingredient which can be used according to the invention corresponds to the quantity necessary to obtain the desired result.
- the peptide of sequence (Gly-Pro-Gln)n-NH 2 is used in a concentration representing from 0.0005 to 500 ppm (parts per million), and preferentially, in a concentration representing from 0.05 to 50 ppm (parts per million).
- the peptide of sequence (Gly-Pro-Gln) 2 -NH 2 is used in a concentration representing from 0.0005 to 500 ppm (parts per million), and preferentially, in a concentration representing from 0.05 to 50 ppm (parts per million).
- compositions according to the present invention will be in a pharmaceutical form, adapted to a topical use, and cover all the cosmetic or dermatological forms. These compositions must thus contain a medium compatible with use in the cosmetic field, i.e. which is compatible with the skin or hairs.
- compositions can be, in particular, in the form of a cream, a water-in-oil or oil-in-water emulsions, or multiple emulsion, a solution, a suspension, or a powder, adapted to skin, lips and/or hair application.
- compositions can be more or less fluid and have the aspect of a cream, a lotion, a milk, a serum, a pomade, a gel, a paste or a foam. They may also consist of a solid form, such as a stick or they may also be applied on the skin as an aerosol. These compositions can be used as skin-care products and/or as make-up products for the skin.
- compositions can also contain, in a known way, the necessary adjuvants for the formulation, that are common in the corresponding fields, such as solvents, thickeners, thinners, antioxidants, dyestuffs, screening agents, pigments, fillers, preservatives, perfumes or odour absorbers.
- these adjuvants and their proportions will be selected to cause no harm to the properties of the composition.
- the quantities of these various adjuvants are those conventionally used in the cosmetic field, for example from 0.01 to 20% relative to the total weight of the composition.
- the proportion of the fatty phase may range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
- the emulsifiers and coemulsifiers used in the composition are chosen from those conventionally used in the cosmetic field. For example, they may be used in the composition in a proportion ranging from 0.3 to 30% by weight relative to the total weight of the composition.
- an another subject of the invention is a cosmetic or a dermatological composition
- a cosmetic or a dermatological composition comprising, in a medium which is compatible with use in the cosmetic or the pharmaceutical field, a sufficient amount of peptide of sequence (Gly-Pro-Gln) n -NH 2 .
- the peptide of said composition has the sequence (Gly-Pro-Gln) 2 -NH 2 .
- the peptide of sequence (Gly-Pro-Gln) n -NH 2 is used in a concentration representing between 0.0005 and 500 ppm (parts per million), and preferably, between 0.05 and 50 ppm (parts per million).
- the peptide of sequence (Gly-Pro-Gln) 2 -NH 2 is used in a concentration representing between 0.0005 and 500 ppm (parts per million), and preferably, between 0.05 and 50 ppm (parts per million).
- the invention finally, relates to a cosmetic treatment process for the treatment of the manifestations of aging, consisting in skin or hair application of the composition described above.
- the Peptide (Gly-Pro-Gln)2-NH2 was analyzed with a concentration of 10-4 M by HPLC on a column of the C18 type, and with a linear gradient water/TFA 0.1% -acetonitril/TFA 0.1%. After 24 hours at various temperatures (25° C., 37° C. and 60° C.), no decomposition of peptide was observed. Moreover, after 8 days at 25° C., no peptide degradation was obtained.
- a test is carried out by applying the peptide to the fibroblasts and to the keratinocytes in culture.
- a HPLC analysis of the culture medium reveals that the peptide concentration decreases quickly, i.e. in a few hours.
- the study is carried out in 96 wells micro-plates on keratinocytes cultured in an incubator at 37° C. and 5% of CO 2 .
- Condition A negative control, not containing peptide
- Condition B incubated with various peptides, made up from 3 to 25 amino acids, with a concentration of 35 ppm;
- Condition C incubated with collagen of the type I with a concentration of 60 ppm;
- Condition D incubated with the peptide of sequence (Gly-Pro-Gln)2-NH2 to a concentration of 5 ppm.
- the wells are completely filled with medium, hermetically closed, turned over and agitated on a three-dimensional agitator during 20 minutes. Then the plates are emptied and the remaining medium is aspired. Then, 100 ⁇ l of MTT with 1 mg/ml are added by wells and are left for 3 hours at 37° C. and 5% CO 2 . The solution is finally withdrawn, then 100 ⁇ l of DMSO is added. A reading of the OD is made at 560 nm against 630 nm.
- compositions were obtained by simple mixture of the various components. The quantities indicated are percentages by weight.
- Oily phase Cetearyl Alcohol (and) Cetearyl Glucoside 5.00% Jojoba Oil 5.00% Mineral Oil 5.00% Isopropyl Palmitate 7.00%
- Aqueous phase Glycerin 5.00% Allantoin 0.10% Peptide of example 1 1 ppm Polyacrylamide (and) C13-14 Isoparaffin (and) Laureth-7 0.30% Preservative 0.50% Fragrance 0.50% Water qs 100%
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The invention concerns the uses for the preparation of a cosmetic or dermatological composition, of a sufficient amount of peptide of sequence (Gly-Pro-Gln)n-NH2, wherein n ranges between 1 and 3, and where the amino acids can be in the L, D, or DL configuration; the peptides or the composition being designed to:
- promote adhesion between cutaneous cells,
- promote cell adhesion,
- provide curative and/or preventive treatment for aging skin symptoms (of physiological or solar origin) and to enhance skin appearance.
- In a preferred embodiment of the invention, said peptide is of the sequence (Gly-Pro-Gln)2-NH2.
- Cutaneous aging is a complex phenomenon due to many intrinsic and extrinsic factors. Clinically, wrinkles and fine lines appear, as well as a loss of cutaneous elasticity, a slackening of cutaneous and subcutaneous tissues . . .
- Many ways of research are proposed to fight against aging, such as protection against the environment (sun, pollution . . . ), activation of cellular regeneration, reinforcement of the extracellular matrix (collagen and elastin). Recently, studies have shown the importance of the keratinocytes adhesion on the dermo-epidermal junction in the treatment of skin aging.
- In a general way, by increasing cell adhesion between them, and cell-extracellular matrix adhesion, it is possible to prevent, even to treat, the slackening of the skin.
- Very few studies have been conducted on this subject despite the fact it offers promising results, whereas the adhesion between the cells and the matrix can support exchanges that we know, now, to be numerous between the cell and its complex environment.
- The collagen is a principal element of the extracellular matrix and takes part in skin structure and consistency. Collagen is studies a lot for its many functions and is also abundantly used in cosmetics.
- Although the use of collagen was reduced due to BSE problems, collagen still remains very used through marine collagens (native and hydrolysed). Recently, the cosmetic industry was aware of the use of peptides in cutaneous biology (such as sequences derived from alpha-MSH, some neuropeptides), and is in search of peptides having a high activity at the cutaneous level.
- Also it is logical to see many studies on peptide sequences trying to imitate the activity of collagen. These sequences try to approach either to a specific area of collagen, or to its very particular form. Need therefore continues to exist for a new derivative of collagen, which has an effect on adhesion on cutaneous cells.
- However, the inventors found in a surprising and unexpected way that an effective amount of a peptide of sequence (Gly-Pro-Gln)n-NH2 has an effect on cell adhesion. It was, heretofore, never described, in the former art, such use of a peptide of sequence (Gly-Pro-Gln)n-NH2 in cosmetics.
- Thus, the main subject of the invention is the use for preparing a cosmetic or dermatological composition, of a sufficient amount of peptide of sequence (Gly-Pro-Gln)n-NH2, wherein n ranges between 1 an 3, and where the amino acids can be in the L, D, or DL configuration ; the peptides or the composition being designed to increase cell adhesion.
- More particularly according to the invention, the peptides or the composition are designed to promote adhesion between cutaneous cells.
- Thereafter, the term “cellular adhesion” intends, on the one hand, the adhesion between cells and the extracellular matrix, and, on the other hand, the adhesion of cells between them. The term “adhesion between the cutaneous cells”, intends, on the one hand, the adhesion between cutaneous cells and the extracellular matrix, and on the other hand, the adhesion of cutaneous cells between them.
- The expression “to increase cell adhesion”, intends the stimulation of the protein expression aiming at reinforcing cell adhesion and enriching the extracellular matrix with proteins which compose it.
- Thus, the peptide or the composition according to the invention, increases the protein expression of the extracellular matrix. There may be mentioned, by way of example of proteins of the extracellular matrix, proteins such as collagen, fibronectin, laminin or elastin. All these proteins are constitutive of the matrix and play a fundamental role.
- The laminin-5, for example, interacts with the integrins of basal keratinocytes, which permit thus to anchor the cells on the two-dimensional network of the dermo-epidermal junction.
- Cell adhesion is carried out, in particular, thanks to membrane glycoproteines, the integrins. These proteins interact with various molecules of the extracellular matrix, like fibronectin or laminin. They are involved in the keratinocyte adhesion to the extracellular matrix, in the connections between cells and in the basement membrane cohesion of the skin. Thus, an increase in the adherent capacity of the cutaneous cells can indicate an increase of the integrin expression.
- Moreover, the reinforcement of the cell adhesion makes it possible to preserve the structure of collagen fibers and to fight cutaneous atrophy due to aging, in particular with photoinduced aging. The peptide, according to the invention, acts on cohesion, communication and on the three-dimensional organization of the cutaneous tissues, thus supporting the fight against the structural disorganization due to cutaneous aging.
- Thus, the invention also concerns the uses for preparing a cosmetic or dermatological composition, of an effective amount of peptide of sequence (Gly-Pro-Gln)n-NH2, wherein n ranges between 1 an 3, and where the amino acids can be in the L, D, or DL configuration; the peptides or the composition being designed to provide curative and/or preventive treatment for aging skin symptoms and to enhance skin appearance.
- The expression “to enhance skin appearance” intends all the phenomena which are likely to have for consequences a visual improvement of the skin's aspect. The skin will have a nicer appearance; it will be, for example, much more beautiful, firm and/or smooth. All the small imperfections will be decreased or removed. The papyraceous aspect of the skin, for example, will be attenuated.
- The term “cutaneous signs of aging” intends any modification in the external appearance of the skin due to aging, whether chronobiological and/or photoinduced, such as, for example wrinkles and fines lines, withered skin, flabby skin, thinned skin, or lack of elasticity and/or tonicity of the skin, but also all internal modifications of the skin which do not result systematically in a modified external appearance, such as, for example, all internal damages of the skin, particularly to collagen, resulting from ultraviolet radiations exposure.
- Skin aging can be, for example, a quantitative and a qualitative deterioration of interactions between the various components of the extracellular matrix, and can result in the appearance of wrinkles and fine lines. These deteriorations are particularly severe in areas exposed to UV. Indeed, fibroblasts exposed to UV adhere slightly more to fibronectin, and has as a consequence a degradation of collagen fibers.
- Actually, in a preferred embodiment of the invention, said peptide is of the sequence (Gly-Pro-Gln)2-NH2.
- It may be necessary, for a resistance to degradation, to use a protected form of the peptide according to the invention. Obviously, the form of protection must be a biologically compatible form and must be compatible with use in the cosmetic or the pharmaceutical field.
- Many biologically compatible forms of protection can be considered; they are well known by a person skilled in the art, like, for example, the acylation or the acetylation of the N-terminal amine group, or the amidation or the esterification of the terminal carboxyl group.
- Thus, the invention relates to the use such as previously defined characterized by the fact that the peptide is in a protected form or not. Preferably, the protection used is either the acylation of the N-terminal amine group, or the esterification of the terminal carboxyl group, or both of them.
- In the field of amino acids, the geometry of the molecules is such that they can be theoretically presented as different optical isomers. There is indeed a molecular conformation of the amino acid (AA) such that it deviates on the right the plan of polarization of the light (dextrogyre conformation or D-aa), and a molecular conformation of the amino acid (aa) such that it deviates on the left the plan of polarization of the light (levogyre conformation or L-aa). Nature retained for the natural amino acids only levogyre conformation. Consequently, a peptide of natural origin will be made up only of amino acids of type L-aa.
- However, the chemical synthesis in laboratory makes it possible to prepare amino acids having two possible conformations. From this basic material, it is thus possible to incorporate during the peptide synthesis, amino acids in the form of dextrogyre or levogyre optical isomers.
- Thus, the amino acids, constituting the peptide according to the invention, can be under configuration L and D; in a preferential way, amino acids have L configuration. Thus, the peptide according to the invention can be in L, D, or DL configuration.
- Peptides, the objects of this patent, can be obtained either by traditional chemical synthesis (in solid phase or in homogeneous liquid phase), or by enzymatic synthesis (Kullman and Al, J Biol. Chem. 1980, 225, 8234) from constitutive amino acids or their derivatives. Peptides of this invention can still be obtained by biotechnology (use of a micro-organism, modified or not by genetic engineering); i.e., peptides according to this invention can also be obtained by fermentation of a strain of bacteria, modified or not, by genetic engineering to produce peptides of sequence previously mentioned and their fragments. Peptides of this invention can also be obtained from natural proteins; i.e. by protein extraction of animal or vegetable origin, followed by controlled hydrolysis which releases the peptide fragments of average size and of small size, with the condition that the released elements must contain at least the sequence (Gly-Pro-Gln)-NH2.
- It is possible, but non necessary, to carry out the invention to extract either the proteins concerned initially and then to hydrolyse them, or to initially carry out the hydrolysis on raw extract and then to purify the peptide fragments.
- Other simpler or more complex processes can be considered by the specialist of the profession who is experienced in synthesis, extraction and purification of proteins and peptides.
- Thus, the peptide of the invention may be of natural or synthetic origin. Preferably, the peptide of the invention is obtained by chemical synthesis.
- According to another aspect of the present invention, the peptide, mentioned above, is solubilized beforehand in one or more solvents compatible with use in the cosmetic or the pharmaceutical field, such as water, glycol propylene, glycol butylene, diglycols ethoxylated or propoxylated , ethanol, propanol or isopropanol.
- According to another aspect of the present invention, the peptide, mentioned above, is solubilized beforehand in one or more vectors such as liposomes or adsorbed on powdery organic polymers, mineral supports like talcs and bentonites, and more generally solubilized in, or fixed on, any vector compatible with use in the cosmetic or the pharmaceutical field.
- The composition, according to the invention, can be a cosmetic or a dermatological or a pharmaceutical composition. Preferentially, according to the invention, the composition is a cosmetic composition, because it is intended to improve the aspect and the general cutaneous performances of the skin.
- The composition, according to the invention, is preferentially a cosmetic and/or a dermatological composition, adapted to a cutaneous administration, including a medium compatible with a use in the cosmetics or the pharmaceutical field.
- Obviously, the invention concerns the mammals in general and, more particularly, human beings.
- The effective amount of the active ingredient which can be used according to the invention corresponds to the quantity necessary to obtain the desired result.
- To give an order of magnitude, in the cosmetic or dermatological compositions of this invention, the peptide of sequence (Gly-Pro-Gln)n-NH2 is used in a concentration representing from 0.0005 to 500 ppm (parts per million), and preferentially, in a concentration representing from 0.05 to 50 ppm (parts per million).
- To give an order of magnitude, in the cosmetic or dermatological compositions of this invention, the peptide of sequence (Gly-Pro-Gln)2-NH2 is used in a concentration representing from 0.0005 to 500 ppm (parts per million), and preferentially, in a concentration representing from 0.05 to 50 ppm (parts per million).
- Preferentially, the compositions according to the present invention will be in a pharmaceutical form, adapted to a topical use, and cover all the cosmetic or dermatological forms. These compositions must thus contain a medium compatible with use in the cosmetic field, i.e. which is compatible with the skin or hairs.
- These compositions can be, in particular, in the form of a cream, a water-in-oil or oil-in-water emulsions, or multiple emulsion, a solution, a suspension, or a powder, adapted to skin, lips and/or hair application.
- These compositions can be more or less fluid and have the aspect of a cream, a lotion, a milk, a serum, a pomade, a gel, a paste or a foam. They may also consist of a solid form, such as a stick or they may also be applied on the skin as an aerosol. These compositions can be used as skin-care products and/or as make-up products for the skin.
- These compositions can also contain, in a known way, the necessary adjuvants for the formulation, that are common in the corresponding fields, such as solvents, thickeners, thinners, antioxidants, dyestuffs, screening agents, pigments, fillers, preservatives, perfumes or odour absorbers. In any case, these adjuvants and their proportions, will be selected to cause no harm to the properties of the composition. The quantities of these various adjuvants are those conventionally used in the cosmetic field, for example from 0.01 to 20% relative to the total weight of the composition.
- When the composition of the invention is an emulsion, the proportion of the fatty phase may range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition. The emulsifiers and coemulsifiers used in the composition are chosen from those conventionally used in the cosmetic field. For example, they may be used in the composition in a proportion ranging from 0.3 to 30% by weight relative to the total weight of the composition.
- Of course, the expert will take care to choose the possible complementary compounds, active or inactive ingredients, and/or their quantities, so that the advantageous properties of the mixture are not deteriorated by the addition considered.
- Also, an another subject of the invention is a cosmetic or a dermatological composition comprising, in a medium which is compatible with use in the cosmetic or the pharmaceutical field, a sufficient amount of peptide of sequence (Gly-Pro-Gln)n-NH2. Preferentially, the peptide of said composition has the sequence (Gly-Pro-Gln)2-NH2.
- In the composition according to the invention, the peptide of sequence (Gly-Pro-Gln)n-NH2 is used in a concentration representing between 0.0005 and 500 ppm (parts per million), and preferably, between 0.05 and 50 ppm (parts per million).
- In the composition according to the invention, the peptide of sequence (Gly-Pro-Gln)2-NH2 is used in a concentration representing between 0.0005 and 500 ppm (parts per million), and preferably, between 0.05 and 50 ppm (parts per million).
- The invention, finally, relates to a cosmetic treatment process for the treatment of the manifestations of aging, consisting in skin or hair application of the composition described above.
- Other advantages and characteristic of the invention will better appear with the reading of the examples given as an illustrative without limiting it in any way.
- The Peptide (Gly-Pro-Gln)2-NH2 was analyzed with a concentration of 10-4 M by HPLC on a column of the C18 type, and with a linear gradient water/TFA 0.1% -acetonitril/TFA 0.1%. After 24 hours at various temperatures (25° C., 37° C. and 60° C.), no decomposition of peptide was observed. Moreover, after 8 days at 25° C., no peptide degradation was obtained.
- Human fibroblasts and keratinocytes were cultivated during 24 hours at 37° C. and 5% of CO2. For this period, the cells will release many degradation enzymes in the culture medium. Thereafter, the culture medium is removed to be put in the presence of the peptide. The results of the analyses show that after 24 hours, the peptide presents almost no degradation.
- A test is carried out by applying the peptide to the fibroblasts and to the keratinocytes in culture. A HPLC analysis of the culture medium reveals that the peptide concentration decreases quickly, i.e. in a few hours.
- These results, taken as a whole, suggest the possibility of a penetration of peptide in the cell. This assumption is then consolidated by the tests of effectiveness exposed in the example 2.
- The study is carried out in 96 wells micro-plates on keratinocytes cultured in an incubator at 37° C. and 5% of CO2.
- The wells of these plates are pre-treated, for 12 hours, in different ways; four conditions have been realized
- Condition A: negative control, not containing peptide;
- Condition B: incubated with various peptides, made up from 3 to 25 amino acids, with a concentration of 35 ppm;
- Condition C: incubated with collagen of the type I with a concentration of 60 ppm;
- Condition D: incubated with the peptide of sequence (Gly-Pro-Gln)2-NH2 to a concentration of 5 ppm.
- After 3 hours of contact with the keratinocytes, the wells are completely filled with medium, hermetically closed, turned over and agitated on a three-dimensional agitator during 20 minutes. Then the plates are emptied and the remaining medium is aspired. Then, 100 μl of MTT with 1 mg/ml are added by wells and are left for 3 hours at 37° C. and 5% CO2. The solution is finally withdrawn, then 100 μl of DMSO is added. A reading of the OD is made at 560 nm against 630 nm.
- The results show various Optical Densities (OD) obtained according to the various conditions. The OD is proportional to the quantity of viable cells, i.e. which adhered to the micro-plates.
Conditions A B C D O.D. 0.490 0.490 0.680 0.620 - These results show, that only after 3 hours of contact with the keratinocytes, the peptide of sequence (Gly-Pro-Gln)2-NH2 brings a good cell adhesion, similar to that of the collagen of the type I, although the peptide was used in a lower concentration than collagen (10 times lower).
- These compositions were obtained by simple mixture of the various components. The quantities indicated are percentages by weight.
- 1—Oil-in-Water Emulsion
- Oily phase:
Cetearyl Alcohol (and) Cetearyl Glucoside 5.00% Jojoba Oil 5.00% Mineral Oil 5.00% Isopropyl Palmitate 7.00% - Aqueous phase:
Glycerin 5.00% Allantoin 0.10% Peptide of example 1 1 ppm Polyacrylamide (and) C13-14 Isoparaffin (and) Laureth-7 0.30% Preservative 0.50% Fragrance 0.50% Water qs 100% - 2—Gel
Carbomer (solution 2%) 25.00% Triethanolamine 0.50% Peptide of example 1 0.1 ppm Preservative 0.20% EDTA 0.10% Fragrance 0.50% Water qs 100% - 3—Lotion
Propylen Glycol 1.00% Allantoin 0.30% Glycerin 1.00% PEG-7 Glyceryl Cocoate 1.00% Peptide of example 1 10 ppm Preservative 0.20% Fragrance 0.50% Water qs 100%
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0109366 | 2001-07-13 | ||
FR0109366A FR2827170B1 (en) | 2001-07-13 | 2001-07-13 | USE OF PEPTIDES TO INCREASE CELL ADHESION |
PCT/FR2002/002380 WO2003007905A2 (en) | 2001-07-13 | 2002-07-08 | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/002380 Continuation WO2003007905A2 (en) | 2001-07-13 | 2002-07-08 | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040142873A1 true US20040142873A1 (en) | 2004-07-22 |
US7211269B2 US7211269B2 (en) | 2007-05-01 |
Family
ID=8865476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/755,277 Expired - Lifetime US7211269B2 (en) | 2001-07-13 | 2004-01-13 | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells |
Country Status (6)
Country | Link |
---|---|
US (1) | US7211269B2 (en) |
EP (1) | EP1406589B1 (en) |
AU (1) | AU2002330556A1 (en) |
ES (1) | ES2604753T3 (en) |
FR (1) | FR2827170B1 (en) |
WO (1) | WO2003007905A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023077338A1 (en) * | 2021-11-04 | 2023-05-11 | 深圳市维琪科技股份有限公司 | Hexapeptide derivative and cosmetic composition or pharmaceutical composition and use thereof |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1575605B1 (en) * | 2002-11-08 | 2011-04-13 | Société d'Extraction des Principes Actifs (Vincience SA) | Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser |
ES2293753B1 (en) * | 2004-04-28 | 2009-03-16 | Lipotec, S.A. | USE OF XIKVAV PEPTIDES IN PREPARATION OF COSMETIC COMPOSITIONS TO IMPROVE SKIN FIRMING THROUGH THE INCREASE OF CELLULAR ADHESION. |
JP5324781B2 (en) * | 2004-06-14 | 2013-10-23 | ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス | Cosmetics containing PTH fragments |
FR2893501B1 (en) | 2005-11-21 | 2014-03-14 | Oreal | TOPICAL COMPOSITIONS FOR PROMOTING SKIN HOMEOSTASIS |
FR2893502A1 (en) | 2005-11-21 | 2007-05-25 | Oreal | Cosmetic skincare method, useful e.g. for combating skin ageing, comprises simultaneous/sequential application of composition comprising agent increasing expression of mechanoreceptors in cells, and device |
JP4966084B2 (en) | 2007-04-25 | 2012-07-04 | エスアイアイ・プリンテック株式会社 | Ink jet head driving method, ink jet head, and ink jet recording apparatus |
AU2008345068A1 (en) * | 2007-12-26 | 2009-07-09 | Mark A. Pinsky | Collagen formulations for improved skin care |
FR3034664B1 (en) | 2015-04-09 | 2018-09-14 | ISP Investments LLC. | HYDRO-ALCOHOLIC EXTRACT OF SCHINUS MOLLE, COSMETIC COMPOSITIONS COMPRISING SAME AND THEIR COSMETIC USES |
FR3043695B1 (en) | 2015-11-17 | 2019-10-25 | ISP Investments LLC. | PROCESS FOR OBTAINING AQUEOUS EXTRACT ENRICHED IN SMALL RNA FROM PLANT MATERIAL AND EXTRACTS FROM THE PROCESS |
FR3048610B1 (en) | 2016-03-08 | 2020-03-27 | ISP Investments LLC. | ACTIVE FAT AND / OR ACTIVATED WAX USING THE NON-WATER-SOLUBLE FRACTION OF CARICA PAPAYA SUC |
WO2018048864A1 (en) | 2016-09-07 | 2018-03-15 | Isp Investments Llc | Aqueous extract of prunus persica and process for preparing the same |
ES2972007T3 (en) | 2016-10-31 | 2024-06-10 | Sytheon Ltd | Compositions and methods to improve skin |
FR3062568B1 (en) | 2017-02-09 | 2020-10-23 | Isp Investments Llc | EXTRACTS OF LIANE MARSDENIA CUNDURANGO, COSMETIC COMPOSITIONS INCLUDING THEM AND THEIR COSMETIC USES. |
CN108721155B (en) | 2017-04-14 | 2023-03-17 | Isp投资有限公司 | Cosmetic preparation containing white truffle extract and cosmetic method thereof |
FR3066113B1 (en) | 2017-05-12 | 2020-06-05 | ISP Investments LLC. | PROCESS FOR OBTAINING AN AQUEOUS EXTRACT OF GRAVEOLENS ANETHUM ENRICHED IN SMALL RNA |
FR3077204B1 (en) | 2018-01-30 | 2021-09-17 | Isp Investments Llc | MYRCIARIA DUBIA FRUIT EXTRACTS RICH IN ORGANIC ACIDS, COSMETIC COMPOSITIONS CONTAINING IT AND THEIR COSMETIC USES |
FR3091993B1 (en) | 2019-01-29 | 2021-01-22 | Isp Investments Llc | PROCESS FOR OBTAINING AN EXTRACT OF PATCHOULI LEAVES AND ITS COSMETIC USES |
FR3106754B1 (en) | 2020-02-04 | 2022-01-07 | Isp Investments Llc | METHOD FOR OBTAINING AN AQUEOUS LAVENDER EXTRACT, COMPOSITIONS COMPRISING SUCH AN EXTRACT AND THEIR COSMETIC USES |
FR3110425B1 (en) | 2020-05-19 | 2022-09-09 | Isp Investments Llc | METHOD FOR OBTAINING A SANDALWOOD EXTRACT, COMPOSITIONS COMPRISING IT AND COSMETIC USES THEREOF |
CN114081852A (en) | 2020-08-25 | 2022-02-25 | Isp投资有限公司 | Compositions and methods for improving the appearance of skin |
FR3116438B1 (en) | 2020-11-23 | 2022-10-14 | Isp Investments Llc | METHOD FOR OBTAINING AQUEOUS EXTRACTS FROM TEA LEAVES, COMPOSITIONS COMPRISING SUCH EXTRACTS AND THEIR COSMETIC USES |
FR3125425B1 (en) | 2021-07-22 | 2024-09-13 | Isp Invest Llc | BLACK TEA LEAF EXTRACT, COMPOSITIONS COMPRISING IT AND ITS COSMETIC USES |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
US5849323A (en) * | 1997-06-12 | 1998-12-15 | A. Glenn Braswell | Collagen mimetic and method of treating rheumatoid arthritis using same |
US20020091086A1 (en) * | 1999-08-09 | 2002-07-11 | Anders Vahlne | Peptides that block viral infectivity and methods of use thereof |
US6777389B1 (en) * | 1998-11-19 | 2004-08-17 | Connective Tissue Imagineering Llc | Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8803847A0 (en) * | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulatory peptide |
DE4244418A1 (en) * | 1991-12-30 | 1993-07-01 | Gerhard Quelle | Cosmetic and pharmaceutical compsn. contg. specific tri:peptide(s) - is prepd. by controlled hydrolysis of collagen, etc., for stimulating cell respiration or collagen synthesis, etc. |
CA2178711A1 (en) * | 1993-12-23 | 1995-06-29 | Peter David Gluckman | Composition and methods to improve neural outcome |
FR2738746B1 (en) * | 1995-09-19 | 1997-11-14 | Oreal | USE OF AT LEAST ONE PEPTIDE IN A COSMETIC COMPOSITION OR FOR THE PREPARATION OF A MEDICAMENT |
JP2835504B2 (en) * | 1995-12-11 | 1998-12-14 | 末綱 陽子 | Novel peptides and activated oxygen inhibitors |
FR2784029B1 (en) * | 1998-10-05 | 2001-01-05 | Pharmascience Lab | METHOD FOR THE PREVENTION AND / OR COSMETIC TREATMENT OF STRETCH MARKS AND USE IN DERMATOLOGY |
AU2001275018B2 (en) * | 2000-05-30 | 2008-04-03 | Connective Tissue Imagineering Llc | Composition and method for enhancing elasticity of tissue |
WO2002016408A2 (en) * | 2000-08-24 | 2002-02-28 | Neuronz Ltd. | Gpe analogs |
FR2893502A1 (en) * | 2005-11-21 | 2007-05-25 | Oreal | Cosmetic skincare method, useful e.g. for combating skin ageing, comprises simultaneous/sequential application of composition comprising agent increasing expression of mechanoreceptors in cells, and device |
-
2001
- 2001-07-13 FR FR0109366A patent/FR2827170B1/en not_active Expired - Fee Related
-
2002
- 2002-07-08 ES ES02767553.7T patent/ES2604753T3/en not_active Expired - Lifetime
- 2002-07-08 AU AU2002330556A patent/AU2002330556A1/en not_active Abandoned
- 2002-07-08 EP EP02767553.7A patent/EP1406589B1/en not_active Expired - Lifetime
- 2002-07-08 WO PCT/FR2002/002380 patent/WO2003007905A2/en not_active Application Discontinuation
-
2004
- 2004-01-13 US US10/755,277 patent/US7211269B2/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
US5849323A (en) * | 1997-06-12 | 1998-12-15 | A. Glenn Braswell | Collagen mimetic and method of treating rheumatoid arthritis using same |
US6777389B1 (en) * | 1998-11-19 | 2004-08-17 | Connective Tissue Imagineering Llc | Cosmetic or dermatological use of 7-hydroxylated steroids in combination with elastin derived peptides |
US20020091086A1 (en) * | 1999-08-09 | 2002-07-11 | Anders Vahlne | Peptides that block viral infectivity and methods of use thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023077338A1 (en) * | 2021-11-04 | 2023-05-11 | 深圳市维琪科技股份有限公司 | Hexapeptide derivative and cosmetic composition or pharmaceutical composition and use thereof |
CN116801857A (en) * | 2021-11-04 | 2023-09-22 | 深圳市维琪科技股份有限公司 | Hexapeptide derivative and cosmetic composition or medicinal composition and application thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2604753T3 (en) | 2017-03-09 |
AU2002330556A1 (en) | 2003-03-03 |
WO2003007905A2 (en) | 2003-01-30 |
EP1406589A2 (en) | 2004-04-14 |
WO2003007905A3 (en) | 2003-11-06 |
FR2827170B1 (en) | 2004-07-16 |
EP1406589B1 (en) | 2016-09-07 |
FR2827170A1 (en) | 2003-01-17 |
US7211269B2 (en) | 2007-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7211269B2 (en) | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells | |
US7396815B2 (en) | Cosmetic or pharmaceutical composition containing peptides | |
US7674451B2 (en) | Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes | |
US20040141939A1 (en) | Cosmetic or dermatological use of peptides for promoting adhesion between skin cells | |
US8435950B2 (en) | Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same | |
US8877713B2 (en) | Anti-aging peptides and cosmetic and/or pharmaceutical composition containing same | |
EP2164858B1 (en) | Kghk peptide, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same | |
US8809276B2 (en) | Activator peptides for synthesizing extracellular matrix proteins, and cosmetic compositions including same | |
ES2360388T3 (en) | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDES WITH THE ARG-GLY-SER SEQUENCE. | |
US9199101B2 (en) | Use of a peptide hydrolysate of pea as moisturizing active agent | |
US8450456B2 (en) | Activating peptide of the synthesis of aquaporins and cosmetic and/or pharmaceutical composition containing it | |
US8044027B2 (en) | Utilization of peptides as active ingredients for slimming | |
CN109923122A (en) | New type of peptides and the cosmetic combination for inhibiting skin aging or wrinkle of skin to be formed comprising it | |
US7737119B2 (en) | Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes | |
KR102475100B1 (en) | Preparing method of highly functional peptide derived from keratinocyte protein | |
US8012938B2 (en) | Dermatological and/or cosmetic composition containing polypeptides | |
KR102619897B1 (en) | Novel peptides and cosmetic compositions for enhancing skin barrier or inhibiting skin pruritus comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS S.A., FR Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAL FARRA, CLAUDE;DOMLOGE, NOUHA;REEL/FRAME:019005/0750 Effective date: 20070312 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |